Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Temozolomide in Glioblastoma
NCT04091503Phase 1Completed
- Sponsor
- Center Trials & Treatment Europe
- Start
- Dec 2019
- Primary completion
- Sep 2022
- Countries
- 3
01
Overview
Phase 1, randomised, open-label trial of temozolomide in glioblastoma (GBM), Gliosarcoma (GS) and astrocytoma, sponsored by Center Trials & Treatment Europe. Started Dec 2019; status: completed.
02
Drugs
temozolomide
03
Conditions
glioblastoma (GBM)Gliosarcoma (GS)astrocytoma
Beyond the preview
Go deeper on NCT04091503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04091503.